^
Association details:
| Biomarker: | UGT1A9 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Cantabilin (4-methylumbelliferone) (Hyaluronic acid synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular targeting of renal cell carcinoma by an oral combination
Published date:
05/19/2020
Excerpt:
These results demonstrate that the expression of A9 in RCC cells is responsible for SF resistance. However, downregulation of A9 by MU sensitizes cells to SF treatment. Furthermore, SF + MU combination has potent antitumor and antimetastatic efficacy without toxicity.
DOI:
10.1038/s41389-020-0233-0